EVERDIUM Trademark

Trademark Overview


On Sunday, April 25, 2021, a trademark application was filed for EVERDIUM with the United States Patent and Trademark Office. The USPTO has given the EVERDIUM trademark a serial number of 90669884. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Wednesday, October 2, 2024. This trademark is owned by Bausch Health Ireland Limited. The EVERDIUM trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

Pharmaceutical preparations and substances for diagnosis and treatment of oral disease, namely, periodontitis, oral mucousitis and bone and soft tissue regeneration; Medicated pharmaceutical preparations and substances for the treatment and prevention of gastrointestinal diseases and disorders in humans including constipation, hepatic encephalopathy, irritable bowel syndrome, opioid-induced constipation and ulcerative colitis; Medicated beverages, powders, and gels for colonoscopies and endoscopic procedures; Pharmaceutical preparations and substances to prevent and treat diabetes mellitus, epilepsy, migraines, anxiety and depression, chronic pain, headaches, psychiatric disorders, and rare diseases such as Wilson and Huntington's disease, diabetes mellitus, cardiovascular/angina, hyperammonaemia, hormone deficiencies (endocrinology), cancer, otolaryngology, and urinary tract, lungs, heart infections and diseases, central nervous system disorders, neuromuscular conditions, vaginal diso...

Radio frequency medical devices for contracting skin, body sculpting, and soft tissue reconstruction in a non-invasive manner; Medical devices for aesthetic and therapeutic applications for the skin and its subcutaneous structures, namely, a device for delivering energy to the skin and its underlying tissues; Lasers and radio frequency devices for medical and aesthetic treatment; Medical devices, namely, medical instruments designed for the non-invasive removal of human body fat using an external energy source
everdium

General Information


Serial Number90669884
Word MarkEVERDIUM
Filing DateSunday, April 25, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateWednesday, October 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 16, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for diagnosis and treatment of oral disease, namely, periodontitis, oral mucousitis and bone and soft tissue regeneration; Medicated pharmaceutical preparations and substances for the treatment and prevention of gastrointestinal diseases and disorders in humans including constipation, hepatic encephalopathy, irritable bowel syndrome, opioid-induced constipation and ulcerative colitis; Medicated beverages, powders, and gels for colonoscopies and endoscopic procedures; Pharmaceutical preparations and substances to prevent and treat diabetes mellitus, epilepsy, migraines, anxiety and depression, chronic pain, headaches, psychiatric disorders, and rare diseases such as Wilson and Huntington's disease, diabetes mellitus, cardiovascular/angina, hyperammonaemia, hormone deficiencies (endocrinology), cancer, otolaryngology, and urinary tract, lungs, heart infections and diseases, central nervous system disorders, neuromuscular conditions, vaginal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations and substances for the treatment of skin and nail conditions, namely, acne, psoriasis, onychomycosis, tinea pedis, actinic keratosis, rosacea and other dermatoses, fungal infections; Vitamins and mineral supplements
Goods and ServicesRadio frequency medical devices for contracting skin, body sculpting, and soft tissue reconstruction in a non-invasive manner; Medical devices for aesthetic and therapeutic applications for the skin and its subcutaneous structures, namely, a device for delivering energy to the skin and its underlying tissues; Lasers and radio frequency devices for medical and aesthetic treatment; Medical devices, namely, medical instruments designed for the non-invasive removal of human body fat using an external energy source

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 30, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateFriday, July 30, 2021
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBausch Health Ireland Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDUBLIN 24
IE

Party NameBausch Health Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDUBLIN 24
IE

Trademark Events


Event DateEvent Description
Friday, July 30, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, April 28, 2021NEW APPLICATION ENTERED
Saturday, October 16, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, October 16, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, October 16, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, October 16, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, October 16, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, December 1, 2021ASSIGNED TO EXAMINER
Wednesday, December 1, 2021NON-FINAL ACTION WRITTEN
Wednesday, December 1, 2021NON-FINAL ACTION E-MAILED
Wednesday, December 1, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 7, 2022EXAMINERS AMENDMENT -WRITTEN
Thursday, July 7, 2022EXAMINERS AMENDMENT E-MAILED
Thursday, July 7, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, July 7, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, July 12, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 27, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 16, 2022PUBLISHED FOR OPPOSITION
Tuesday, August 16, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, August 22, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, August 22, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 22, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, December 28, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Tuesday, October 11, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 14, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, January 18, 2023ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, April 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 9, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, October 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 8, 2023ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Monday, April 3, 2023SOU TEAS EXTENSION RECEIVED
Monday, April 3, 2023SOU EXTENSION 1 FILED
Monday, April 3, 2023SOU EXTENSION 1 GRANTED
Monday, October 9, 2023SOU EXTENSION 2 FILED
Monday, October 9, 2023SOU EXTENSION 2 GRANTED
Monday, April 1, 2024SOU EXTENSION 3 FILED
Monday, April 1, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, October 2, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, October 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 2, 2024SOU EXTENSION 4 FILED
Wednesday, October 2, 2024SOU EXTENSION 4 GRANTED
Tuesday, April 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 1, 2024SOU EXTENSION 3 GRANTED